Meta‐analysis: hepatitis B reactivation in patients receiving biological therapy
Authors:
- 17 August 2022
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (7) , 1104-1118
Abstract
Summary: Background: The use of biologics poses a moderate to high risk for hepatitis B virus reactivation (HBVr) in chronic carriers.Aim: To determine the prevalence of HBVr with TNF alpha inhibitors, ustekinumab and vedolizumabMethod: We followed the MOOSE guidelines and conducted a comprehensive literature search. We conducted a systematic search of EMBASE (Ovid), MEDLINE (Ovid) and PubMed. The studies included patients who were chronic and occult HBV carriers with various rheumatological, dermatological or gastroenterological conditions. We used a random effects model using pooled estimates (prevalence of HBVr with 95% confidence intervals (CI)).Results: We included 29 studies with 1409 patients infected with HBV. The prevalence of HBVr in chronic carriers of HBV was 17.1% (95% CI: 7.0–35.9, n = 5), 16.6% (95% CI: 9.5–27.5%, n = 6), 40.5% (95% CI: 20.3–64.5%, n = 4) and 19.1% (95% CI: 7.3–41.2%, n = 2), respectively, for adalimumab, etanercept, infliximab and ustekinumab. The respective prevalence for reactivation in patients with occult HBV infection was 5.0% (95% CI: 2.8–8.7%, number of studies: n = 18), 2.6% (95% CI: 1.4–4.7%, n = 18), 4.4% (95% CI: 2.2–8.7%, n = 12) and 6.4% (95% CI: 2.2–16.8, n = 5). There were 39 HBVr (26 in chronic HBV and 13 in the occult group) without any hepatic failure or death. In the chronic HBVr group, only three of 24 patients received antiviral prophylaxis.Conclusions: HBVr prevalence rates differ between the chronic carrier state and the occult carrier state. The uptake of prophylactic antiviral therapy in high‐risk groups was low, contrary to clinical practice guidelines.Keywords
This publication has 42 references indexed in Scilit:
- Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseasesInflammatory Bowel Diseases, 2012
- Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapyAnnals of the Rheumatic Diseases, 2011
- Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infectionAnnals of the Rheumatic Diseases, 2010
- Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti–hepatitis B core antigen positive) with rheumatic diseasesArthritis Care & Research, 2010
- Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patientsArthritis Research & Therapy, 2009
- A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trialHepatology, 2008
- A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolizationHepatology, 2006
- Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxisGut, 2004
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986